Skip to Main Content

Paper Details

First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer<sup>â¿¿</sup>.
Ann Oncol
110
2022

Datasets

Release 1.2